In addition, Pinyol et al. reported that in 80 cases of NAFLD-related liver cancer mutations in the TERT promoter were the most common, seen in 56% of cases, similar to the report by Kim et al. In addition, 28% had CTNNB1, 18% had TP53, and 10% had ACVR2A mutations [15]. Here, TP53 is linked to metabolic dysfunction-associated steatotic liver disease.